奥拉帕利单药治疗前列腺切除术后高危生化复发前列腺癌:一项非随机对照试验
这项2期单臂非随机对照试验在美国4个中心纳入51例前列腺切除术后高危生化复发且未筛选基因的前列腺癌患者,给予奥拉帕利300 mg每日两次口服至基线PSA翻倍、临床或影像学进展或不可接受毒性。13例(26%)达PSA50应答,全部位于HRR阳性组(27例中13例,48%),11例BRCA2改变者均达PSA50应答。作者认为奥拉帕利单药在BRCA2改变者中PSA50应答率高且持久,值得进一步研究,但在无HRR改变者中活性不足,不应考虑用于该类患者。
要点
- 51例高危生化复发前列腺癌患者中13例(26%)达PSA50应答,全部在HRR阳性组(27例中13例,48%)。
- 11例BRCA2改变者全部出现PSA50应答。
- 常见不良事件为疲乏32例(63%)、恶心28例(55%)、白细胞减少22例(43%)。
核心结论
- 奥拉帕利单药在BRCA2改变的高危生化复发前列腺癌患者中诱导高且持久的PSA50应答率。
- 奥拉帕利作为部分生化复发前列腺癌患者的治疗策略值得进一步研究,但在无HRR改变者中活性不足,不应考虑用于该类患者。
研究设计与样本
- 2期单臂非随机对照试验,2017年5月至2022年11月在美国4个中心纳入基因未筛选患者。
- 纳入51例男性患者(平均[SD]年龄63.8[6.8]岁),均在前列腺切除术后生化复发,PSA倍增时间≤6个月,PSA绝对值≥1.0 ng/mL,睾酮≥150 ng/dL。
- 干预为奥拉帕利300 mg口服每日两次,直至基线PSA翻倍、临床或影像学进展或不可接受毒性。
主要发现
- 51例中13例(26%)达确证PSA较基线下降≥50%(PSA50),全部位于HRR阳性组(27例中13例,48%)。
- 11例BRCA2改变者全部出现PSA50应答。
- 常见不良事件为疲乏32例(63%)、恶心28例(55%)、白细胞减少22例(43%),与奥拉帕利已知不良反应一致。
关键数值与推荐
- 主要终点为确证PSA较基线下降≥50%(PSA50)。
- 关键次要终点为按HRR改变状态分层的结局以及安全性和耐受性。
临床怎么用
- 原文结论指出奥拉帕利不应考虑用于无HRR改变的患者。
- 原文未据此给出针对BRCA2改变患者的常规推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Olaparib is a poly(adenosine diphosphate-ribose) polymerase inhibitor that provides benefit in combination with hormonal therapies in patients with metastatic prostate cancer who harbor homologous recombination repair (HRR) alterations. Its efficacy in the absence of androgen deprivation therapy has not been tested. OBJECTIVE: To determine the activity of olaparib monotherapy among patients with high-risk biochemically recurrent (BCR) prostate cancer after radical prostatectomy. DESIGN, SETTING, AND PARTICIPANTS: This phase 2, single-arm nonrandomized controlled trial enrolled genetically unselected patients across 4 sites in the US from May 2017 to November 2022. Eligible patients had BCR disease following radical prostatectomy, a prostate-specific antigen (PSA) doubling time of 6 months or shorter, an absolute PSA value of 1.0 ng/mL or higher, and a testosterone level of 150 ng/dL or higher. INTERVENTION: Treatment was with olaparib, 300 mg, by mouth twice daily until doubling of the baseline PSA, clinical or radiographic progression, or unacceptable toxic effects. MAIN OUTCOME AND MEASURE: The primary end point was a confirmed 50% or higher decline in PSA from baseline (PSA50). Key secondary end points were outcomes by HRR alteration status, as well as safety and tolerability. RESULTS: Of the 51 male patients enrolled (mean [SD] age, 63.8 [6.8] years), 13 participants (26%) had a PSA50 response, all within the HRR-positive group (13 of 27 participants [48%]). All 11 participants with BRCA2 alterations experienced a PSA50 response. Common adverse events were fatigue in 32 participants (63%), nausea in 28 (55%), and leukopenia in 22 (43%), and were consistent with known adverse effects of olaparib. CONCLUSIONS AND RELEVANCE: In this nonrandomized controlled trial, olaparib monotherapy led to high and durable PSA50 response rates in patients with BRCA2 alterations. Olaparib warrants further study as a treatment strategy for some patients with BCR prostate cancer but does not have sufficient activity in those without HRR alterations and should not be considered for those patients. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03047135.
引用
- Marshall CH, Teply BA, Lu J, et al. Olaparib Without Androgen Deprivation for High-Risk Biochemically Recurrent Prostate Cancer Following Prostatectomy: A Nonrandomized Controlled Trial. JAMA Oncol. 2024. PMID: 39172479. doi:10.1001/jamaoncol.2024.3074
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。